In the hemophilia A community, no two patients are the same
When finding a treatment for hemophilia A, your patients' individual needs as well as their lives outside the clinic should be taken into account.1
There are many characteristics that make each patient different1,2:
Physical activity and lifestyle
Pharmacokinetic (PK) profile
Infusion dose and frequency
Adherence and prophylaxis
Annualized bleed rate (ABR) and ABR for joint bleeds
Baseline characteristics (eg, age, weight)
Living with hemophilia A will always be an undeniable part of their reality—both the welcome and unwelcome moments. Your patients need treatment options that can help them navigate the many complexities of real life with hemophilia A.
Selected Important Risk Information
Warnings & Precautions
Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.
Please see additional detailed important risk information below.
ADVATE has 15+ years of experience treating hemophilia A in the real world3
ADVATE is a third-generation, full-length molecule, similar to the factor VIII that occurs naturally in the body.3,4
with the latest-generation plasma/albumin-free recombinant factor VIII.3,4
The most widely used
factor VIII product with 33 billion IUs sold globally.8 Based on units sold, as of February 2019.
with evidence spanning over 15 years with 15 prospective studies.3,4,8
Committed to advancing hemophilia A care
In 2003, ADVATE became the first recombinant factor VIII treatment free of blood-based additives. Since then, TAKEDA has made advancements with flexible dosing options, reconstitution with BAXJECT® system, and the introduction of myPKFiT® for PK-guided personalized dosing.3,8
ADVATE [Antihemophilic Factor (Recombinant)]: first recombinant factor VIII (rFVIII) made without added human or animal proteins.3,8
Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):6
Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8(2):237-246. doi:10.1586/17474086.2015.1002465
Advate. Prescribing information. Baxalta US Inc; 2018.
Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186-201. doi:10.1002/biot.200800241
Auerswald G, Thompson AA, Recht M, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012;107(6):1072-1082. doi:10.1160/TH11-09-0642
Khair K, Mazzucconi MG, Parra R, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Haemophilia. 2018;24(1):85-96. doi:10.1111/hae.13361
Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359-367. Published correction appears in J Thromb Haemost. 2012;10(6):1204.
Takeda data on file.
You are now leaving ADVATEPro.com
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.